Gemtuzumab ozogamicin (GO, Mylotarg) is a targeted therapeutic agent in which an anti-CD33 antibody is chemically coupled to a highly cytotoxic calicheamicin derivative through a hydrolysable linker. GO has improved the treatment outcome for a subgroup of acute myeloid leukemia (AML) patients, but its use is associated with severe myelosuppression and hepatotoxicity. Here, we report on a novel anti-leukemia agent, designated scFvCD33:sTRAIL, in which an anti-CD33 single chain fragment of variable regions (scFv) antibody fragment is genetically linked to soluble tumor necrosis factor-related apoptosis-inducing ligand (sTRAIL). Normal CD33-positive monocytes were fully resistant to prolonged treatment with scFvCD33:sTRAIL, whereas treatment with GO resulted in substantial cytotoxicity. The activity of scFvCD33:sTRAIL towards AML cells was up to 30-fold higher than GO. The CD33-restricted anti-leukemia activity of scFvCD33:sTRAIL remained stable during prolonged storage at 37 1C, whereas GO showed a rapid increase in CD33-independent cytotoxicity. Moreover, scFvCD33:sTRAIL showed potent anti-leukemia activity towards CD33 þ CML cells when treatment was combined with the Bcr-Abl tyrosine kinase inhibitor, Gleevec. Importantly, ex vivo treatment of patient-derived CD33 þ AML tumor cells with scFvCD33:sTRAIL resulted in potent apoptosis induction that was enhanced by valproic acid, mitoxantrone and 17-(Allylamino)-17-demethoxygeldanamycin (17-AAG). Taken together, scFvCD33:sTRAIL is superior to GO in terms of tumor selectivity, activity and stability, warranting its further development for the treatment of CD33-positive leukemias.
Introduction
Currently, the prognosis for acute myeloid leukemia (AML) patients is poor with a 5-year survival rate of only 20-30%. 1 This poor prognosis is the result from substantial therapy-related morbidity and mortality and the frequent occurrence of therapyresistant relapses.
2,3 AML cells express several myeloid lineagespecific antigens that may be exploited for antibody-based therapy, with CD33 being best characterized. The expression of CD33 on leukemic blasts is found in approximately 80-90% of AML patients, 4 whereas CD33 expression on normal cells is limited to the myeloid lineage such as monocytes. The unique CD33 expression profile has fueled the clinical development of gemtuzumab ozogamicin (GO), a targeted chemotherapeutic agent in which an anti-CD33 antibody is chemically coupled to a highly cytotoxic calicheamicin derivative through a hydrolysable linker. GO was approved by the FDA in the year 2000 as monotherapy for the treatment of CD33-positive AML in elderly patients who relapsed for the first time and were not eligible for standard chemotherapy regimens. 5 For this subgroup of AML patients efficacy of GO has been reported. 6 The mode of action of GO involves the antibody-mediated selective binding to cell surface-expressed CD33 followed by internalization of GO and the subsequent hydrolytic release of the calicheamicin moiety in the acidic milieu of the lysosome. Next, calicheamicin translocates to the nucleus in which it induces sequence-specific double strand DNA breaks resulting in apoptotic cell death. 7 A prominent side effect of GO treatment is that normal CD33-positive cells, such as monocytes, are also effectively eliminated, leading to severe and sometimes life-threatening myelosuppression. Moreover, the pH-sensitive linker technology used in GO yields conjugates of rather poor thermostability, which can lead to inadvertent release of calicheamicin into the circulation, resulting in toxicity in various normal cells and organs due to CD33-independent uptake of calicheamicin. 8, 9 Moreover, AML cells with reduced or lost CD33 expression can escape from therapy yielding GOrefractory relapses.
Therefore, novel AML-selective approaches are urgently needed that have improved anti-tumor activity that is combined with a more favorable toxicity profile. In this respect, tumor necrosis factor-related apoptosis inducing ligand (TRAIL) seems to be a promising candidate. TRAIL is a tumor-selective proapoptotic effector molecule that is expressed on various immune cells including T and natural killer cells on which it is involved in the elimination of virus-infected and transformed cells. TRAIL interacts with an elaborate receptor system comprising two agonistic receptors, TRAIL-R1 and TRAIL-R2, two antagonistic receptors, TRAIL-R3 and TRAIL-R4, and the soluble receptor osteoprotegerin. TRAIL is expressed as a homotrimeric transmembrane protein (memTRAIL) of which the extracellular domain can be proteolytically cleaved off, yielding soluble TRAIL (sTRAIL). Various recombinant forms of sTRAIL have shown potent tumoricidal activity both in vitro and in various xenografted tumor mouse models, 10, 11 with no or minimal activity towards normal cells. 12, 13 Recently, potent anti-tumor activity of sTRAIL has been reported towards patient-derived AML cells. Herein, low doses of the proteasome inhibitor, bortezomib, primed refractory AML cells for enhanced TRAILmediated killing.
14 These results suggest that TRAIL-based approaches could be effective for treating AML patients, even for patients who are refractory to conventional chemotherapy.
However, the efficacy of conventional recombinant sTRAIL preparations is potentially hampered by the ubiquitous expression of TRAIL-receptors on numerous normal cells and tissues. In addition, TRAIL-R1 and TRAIL-R2 have differential crosslinking requirements for apoptosis signaling, with TRAIL-R2 being less sensitive to sTRAIL than TRAIL-R1. 15 As a result, tumor cells that express TRAIL-R2 over TRAIL-R1 are less sensitive to treatment with sTRAIL.
Earlier, we have shown that these limitations can be largely overcome by fusing a tumor-selective antibody fragment (single chain fragment of variable regions (scFv)) to the N-terminus of human sTRAIL. [16] [17] [18] [19] [20] In one particular fusion protein, designated scFvCD7:sTRAIL, we employed an scFv antibody with specificity for CD7. The cell surface glycoprotein CD7 is abundantly expressed on most T-cell malignancies and B10% of AML. Expression of CD7 on normal blood cells is limited to T cells, thymocytes, natural killer cells and myeloid cells in early hematopoietic cell ontogeny. ScFvCD7:sTRAIL showed potent and CD7-restricted apoptotic activity towards human T-cell acute lymphoblastic leukemia (T-ALL) cells with no or minimal toxicity in normal human blood and endothelial cells. Importantly, in mixed culture experiments of CD7-positive and CD7-negative tumor cells, scFvCD7:sTRAIL induced potent bystander apoptosis in CD7-negative tumor cells. This bystander activity is based on the principle that the targeted tumor cells are not only eliminated, but are also exploited, to crosslink agonistic TRAIL receptors on neighboring tumor cells lacking the target antigen. [16] [17] [18] The anti-tumor bystander activity of the scFv:sTRAIL fusion protein format may prevent the escape from therapy of tumor cells with lost or reduced target antigen expression. Currently, scFvCD7:sTRAIL is being developed for clinical evaluation.
The promising leukemia-selective activity of scFvCD7:sTRAIL and its favorable safety profile prompted us to construct and preclinically evaluate an analogous scFv:sTRAIL fusion protein with engineered specificity for CD33 and to compare it with GO. Here, we describe a novel fusion protein, designated scFvCD33:sTRAIL, that is superior to GO in terms of in vitro tumor selectivity, activity and stability.
Materials and methods

Anti-tumor agents
Stock solutions of mitoxantrone (4.5 mM), 17-(Allylamino)-17-demethoxygeldanamycin (17-AAG) (100 mM) (Sigma Aldrich, Zwijndrecht, The Netherlands) and Gleevec (10 mM) (Novartis Pharma, Arnhem, The Netherlands), were all prepared in DMSO. Stock solutions of valproic acid (VPA) (100 mM) (Sigma Aldrich) and GO (6.6 mM), were prepared in sterile PBS. All stock solutions were aliquoted and subsequently stored at À80 1C until used.
Cell lines, leukocytes, monocytes and primary patient-derived AML cells All cells were cultured in RPMI 1640 (Cambrex, New Jersey, NH, USA) supplemented with 10% FCS, at 37 1C in humidified 5% CO 2 containing atmosphere. The following leukemia-derived cell lines were purchased from the ATCC (Manassas, VA, USA): U-937 (AML, CD33-positive), MonoMac-6 (monocyte/ macrophage-like cell line, CD33-positive), K-562 (chronic myeloid leukemia (CML), CD33-positive) and Jurkat (T-ALL, CD33-negative). Cell line BV-173 (CML, CD33-positive) was purchased from the DSMZ (Braunschweig, Germany). Cell line MOLT-16 (T-ALL, CD33-negative) was a kind gift from Professor Dr Martin Gramatzki, University of Kiel, Germany. CD33-positive Jurkat cells (Jurkat.CD33) were generated by standard electroporation with the eukaryotic expression plasmid pcDNA6.hCD33 21 and subsequent selection procedures. TRAIL-R1 and TRAIL-R2 cell surface expression levels were analyzed using mouse-anti-human TRAIL-R1-and TRAIL-R2-specific antibodies (Alexis, 10P's, Breda, The Netherlands) followed by goat-anti-mouse-PE (Southern Biotech, ITK diagnostics, Uithoorn, The Netherlands). Mononuclear cells (CD33-positive) were isolated from healthy donors by density-gradient centrifugation after which CD14-positive monocytes were isolated by magnetic bead separation (Miltenyi Biotec, Bergisch Gladbach, Germany). Primary AML tumor cells were obtained after informed consent from AML patients by isolation of peripheral blood mononuclear cells using standard densitygradient centrifugation (GE Healthcare, Diegem, Belgium Construction and production of scFvCD33:sTRAIL Fusion protein scFvCD33:sTRAIL was constructed by using the DNA backbone of expression plasmid pEE14-scFvCD7:sTRAIL in which a CD7-selective scFv (scFvCD7) is genetically linked to the N-terminus of human sTRAIL. 16 Briefly, cDNA encoding the CD33-specific antibody fragment scFvCD33 was earlier selected from a scFv phage-display antibody library prepared from the spleen of a CD33-immunized mouse. 21 The cDNA encoding scFvCD7 present in pEE14-scFvCD7:sTRAIL was swapped for the cDNA encoding scFvCD33 by using the SfiI and NotI restriction enzyme sites and standard DNA-cloning techniques, yielding plasmid pEE14-scFvCD33:sTRAIL. Subsequently, this plasmid was transfected in CHO-K1 cells using Fugene-6 reagent (Roche Diagnostics, Almere, the Netherlands). Stable transfectants with amplified expression of fusion protein scFvCD33:sTRAIL were selected by the glutamine synthetase method. 22 Individual clones, obtained after single cell sorting using the MoFlo high-speed cell sorter (Cytomation, Fort Collins, CO, USA), were analyzed for stable and amplified expression of fusion protein scFvCD33:sTRAIL. Culture medium containing fusion protein scFvCD33:sTRAIL was cleared by centrifugation (10 000 g, 10 min), filter sterilized and stored at À80 1C until used.
Analysis of apoptosis induction
The various tumor cell types were seeded at 2.5 Â 10 5 cells per well in a 48-wells plate and treated for 16 h with scFvCD33:sTRAIL at the indicated concentrations. Induction of apoptosis was assessed using one or more of the following apoptosis assays. Exposure of phosphatidylserine: The early apoptotic feature of exposure of phosphatidylserine on the outer membrane was analyzed by flow cytometry using an AnnexinV-FITC/PI kit (NeXins research, Kattendijke, The Netherlands). Loss of mitochondrial membrane potential (Dc): Dc was analyzed by flow cytometry using the cell-permeant greenfluorescent lipophilic dye DiOC6 (Molecular Probes, Eugene, OR, USA). Immunoblot analysis of apoptosis: Induction of apoptosis was assessed by immunoblot analysis using anticaspase 8 (Cell signaling technology, Beverly, MA, USA) and anti-PARP (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Cells were seeded in 6-well plates at a final concentration of 2.0 Â 10 6 cells per well and treated as indicated. Cell lysates were prepared and immunoblot analysis was performed essentially as described earlier. 16 Detection of apoptotic DNA fragmentation: Apoptotic DNA fragmentation was analyzed using mAb F7-26 (Alexis, Kordia Life Sciences, Leiden, The Netherlands).
Percentage of experimental apoptosis was calculated using the following formula: specific apoptosis ¼ (experimental apoptosisÀ spontaneous apoptosis)/(100Àspontaneous apoptosis) Â 100%.
Thermostability of scFvCD33:sTRAIL versus GO
To assess and compare the thermostability of scFvCD33:sTRAIL and GO, stock solutions of scFvCD33:sTRAIL (0.24 mM) and GO The pro-apoptotic activity of scFvCD33:sTRAIL (1.45 mg/ml) towards CD33-positive U-937 and MonoMac-6 AML cells is strongly inhibited in the presence of scFvCD33 (10 mg/ml) or a TRAIL-neutralizing (mAb 2E5, 4 mg/ml). In (c) and (d), apoptosis was assessed by Dc, indicated values are means ± s.e.m. of at least three independent experiments. (e) Treatment with scFvCD33:sTRAIL (1.45 mg/ml) induces caspase 8 and PARP cleavage in MonoMac-6 cells. These apoptotic features are inhibited when treatment is performed in the presence of scFvCD33 (10 mg/ml). (f) Apoptotic DNA fragmentation induced by scFvCD33:sTRAIL(1.45 mg/ml) in MonoMac-6 was assessed by flow cytometric analysis using mAb F7-26. Apoptotic DNA fragmentation is inhibited in the presence of scFvCD33 (10 mg/ml) or mAb 2E5 (4 mg/ml).
(6.58 mM) were stored at 37 1C. After 0, 24, 48 and 72 h of storage, CD33-negative MOLT-16 cells were treated for 16 h with the indicated concentrations of either scFvCD33:sTRAIL or GO. In a control experiment CD33-positive U-937 AML cells were treated with scFvCD33:sTRAIL that was stored for 72 h at 37 1C.
Quantification of bystander activity of scFvCD33:sTRAIL using mixed culture experiments For mixed culture experiments, CD33-positive target tumor cells and CD33-negative bystander tumor cells were differentially labeled using the Vybrant cell-labeling solution DiI (Invitrogen, Breda, The Netherlands). Briefly, Jurkat.CD33 cells were labeled with DiI, whereas Jurkat bystander tumor cells were not labeled. DiI-labeled Jurkat.CD33 cells and non-labeled Jurkat bystander cells were mixed at the indicated ratio at a final concentration of 0.5 Â 10 6 cells per well of a 48-wells plate. After 6 h of treatment with scFvCD33:sTRAIL or scFvC54:sTRAIL, 19 cells were washed twice and incubated overnight; Jurkat.CD33 target cells and Jurkat bystander cells were separately evaluated for apoptosis induction by analysis of Dc.
Activity of caspases 8 and 3/7 was measured in Jurkat.CD33 target and Jurkat bystander tumor cells after 3 h of treatment with scFvCD33:sTRAIL. Thereto, DiI-labeled Jurkat.CD33 target cells and non-labelled Jurkat bystander cells were separated using the MoFlo high-speed cell sorter (Cytomation), and subsequent caspase activation was measured using the Caspase-Glo 8 and 3/7 assay kits (Promega, Almere, The Netherlands) according to the manufacturer's protocol.
Cooperativity index of co-treatment of scFvCD33:sTRAIL with anti-tumor agents
The effect of co-treatment of scFvCD33:sTRAIL with various anti-tumor agents was evaluated by calculation of the cooperativity index (CI), in which the sum of apoptosis induction by a given single-agent treatment is divided by apoptosis induction on co-treatment. CI was qualified as follows: CIo0.9, synergy; 0.9oCIo1.1, additive; CI41.1, antagonistic.
Results and discussion
Here, we report on a novel fusion protein designated scFvCD33:sTRAIL in which an anti-CD33 scFv antibody fragment is genetically linked to sTRAIL (Figure 1a) . ScFvCD33: sTRAIL was designed to have enhanced and CD33-restricted anti-leukemia pro-apoptotic activity, with no or minimal activity towards normal cells.
An eukaryotic expression plasmid encoding the scFvCD33:sTRAIL fusion was constructed and subsequently transfected into CHO-K1 cells. Transfected CHO-K1 cells were selected for stable and amplified secretion of scFvCD33:sTRAIL AML-restricted apoptosis induction by scFvCD33:sTRAIL B ten Cate et al in the culture medium, which identified producer clone 8B2 secreting 36.34 mg/ml. Size-exclusion fast protein liquid chromatography indicated that scFvCD33:sTRAIL was produced as stable and homogeneous trimers in the absence of detectable protein aggregates (data not shown). TRAIL-R1 and TRAIL-R2 expression levels on CD33-negative and CD33-positive cell lines were assessed semiquantitatively ( Table 1 ). The results indicated that all cell lines used in this study express either one or both of the respective TRAIL receptors. Moreover, flow cytometric analysis showed strong and CD33-selective accretion of scFvCD33:sTRAIL at the cell surface of CD33-positive U-937 AML cells, which was inhibited in the presence of a scFvCD33 antibody fragment (Figure 1b) Moreover, binding of scFvCD33:sTRAIL to CD33-negative MOLT-16 (T-ALL) cells was below detectable levels (data not shown). Together this indicates that the binding of scFvCD33:sTRAIL to the cell surface of CD33-positive tumor cells is almost exclusively attributable to its scFvCD33 domain. This can be explained by the fast on/slow off rates that are typical for antibodies and derivatives thereof, whereas TRAIL-TRAIL-receptor-binding rates have very fast on/fast off binding rates typical for cytokine-cytokine-receptor binding. Moreover, trimeric scFvCD33:sTRAIL contains three identical scFv reading heads, which enhances binding to CD33-positive cells by the associated avidity effect. Enhanced avidity has been shown to be beneficial for in vivo tumor targeting in antibodybased therapeutic strategies. 23, 24 Next, we assessed the CD33-targeted apoptosis induction activity of scFvCD33:sTRAIL towards CD33-positive AML cells. Treatment with scFvCD33:sTRAIL at concentrations as low as 72 ng/ml significantly induced apoptosis in U-937 and MonoMac-6 tumor cells (16.7 and 9.1%, respectively. Figure 1c) , and not in CD33-negative MOLT-16 cells. As evident from Table 1 , MOLT-16 T-ALL cells highly express TRAIL-R2. Consequently, AML-restricted apoptosis induction by scFvCD33:sTRAIL B ten Cate et al MOLT-16 cells are relatively insensitive to trimeric sTRAIL, whereas being highly sensitive to memTRAIL. These characteristics are ideally suited to show CD33-restricted activity of scFvCD33:sTRAIL. CD7-positive/CD33-negative MOLT-16 cells proved to be resistant to treatment with scFvCD33:sTRAIL, with concentrations as high as 1.45 mg/ml (Figure 1c) . Importantly, we showed earlier that MOLT-16 cells are highly sensitive to a CD7-selective fusion protein designated scFvCD7:sTRAIL. 16 Fusion protein scFvCD7:sTRAIL is identical to scFvCD33: sTRAIL, except that it contains an anti-CD7 scFv (scFvCD7) instead of scFvCD33.
Apoptosis induction in U-937 and MonoMac-6 cells by scFvCD33:sTRAIL was inhibited in the presence of an scFvCD33 antibody fragment or a TRAIL-neutralizing mAb (Figure 1d) . Apoptosis induction by scFvCD33:sTRAIL was characterized by caspase 8 cleavage (Figure 1e ), PARP cleavage ( Figure 1e ) and apoptotic DNA fragmentation (Figure 1f ). All these TRAILassociated apoptotic features were selectively inhibited when treatment was performed in the presence of scFvCD33 or mAb 2E5 (Figures 1e and f) .
Subsequently, we compared scFvCD33:sTRAIL with GO in terms of potency, toxicity and stability. The anti-leukemia activity of scFvCD33:sTRAIL, GO and the EpCAM-selective fusion protein scFvC54:sTRAIL were compared using CD33-positive/EpCAM-negative U-937 cells. From this experiment the EC 50 for scFvCD33:sTRAIL was calculated to be 2.2 nM, whereas the EC 50 for GO was 71.3 nM. Under the experimental conditions used, the EpCAM-selective fusion protein scFvC54:sTRAIL did not induce apoptosis in U-937 cells (Figure 2a) . These results indicate that scFvCD33:sTRAIL is 32 times more potent than GO, whereas scFvC54:sTRAIL shows no activity towards U-937 cells. A prominent toxic side effect of GO treatment comes from the fact that not only malignant, but also all normal CD33-positive cells, such as monocytes, are targeted for destruction. Therefore, we compared toxicity of scFvCD33:sTRAIL and GO towards freshly isolated human monocytes. Treatment with scFvCD33: sTRAIL showed no signs of toxicity, whereas treatment with GO resulted in a marked induction of apoptosis in B30% of the monocytes (Figure 2b ). This data corroborates with favorable toxicity profiles that we reported earlier for a series of analogous scFv:sTRAIL fusion proteins directed to various tumorassociated antigens, including CD7, CD19, CD20, EpCAM, and EGFR. [16] [17] [18] [19] [20] 25 None of these fusion protein variants showed signs of toxicity towards normal blood cells, endothelia cells and hepatocytes. [16] [17] [18] [19] [20] 25 From this we conclude that the intrinsic tumor-selective activity of sTRAIL is fully retained in the scFvCD33:sTRAIL fusion protein.
The anti-leukemia activity of GO critically relies on the timely intracellular release of the calicheamicin after internalization into CD33-positive tumor cells. However, the linker technology used in GO yields conjugates of rather poor thermostability, which can result in the inadvertent release of calicheamicin in the circulation and subsequent systemic toxicity due to CD33-independent uptake of calicheamicin in normal cells and tissues. We compared the thermostability and associated untargeted toxicity of scFvCD33:sTRAIL and GO by storing them for up to 72 h at 37 1C. This revealed that CD33-negative MOLT-16 cells were fully resistant to scFvCD33:sTRAIL samples from all storage time points evaluated, whereas treatment with identically stored GO resulted in a steep timedependent apoptosis induction (Figure 2c) . Importantly, scFvCD33:sTRAIL that was stored for 72 h at 37 1C fully retained its CD33-restricted pro-apoptotic activity towards CD33-positive U-937 cells (data not shown). Taken together, these data suggest a favorable toxicity profile for scFvCD33:sTRAIL, with a strongly reduced risk of myelosuppression and hepatoxicity when systemically applied in human subjects.
It has been reported that target antigen-negative tumor cells can escape from antibody-based therapeutic approaches. 26, 27 Earlier, we showed that scFv:sTRAIL fusion proteins not only eliminated targeted tumor cells, but also conveyed a potent therapeutic bystander effect towards neighboring tumor cells devoid of target antigen expression. Importantly, no toxic innocent bystander activity was observed towards normal cells. 18 In mixed culture experiments of CD33-positive and CD33-negative tumor cells, scFvCD33:sTRAIL induced potent bystander apoptosis in CD33-negative tumor cells. This bystander activity is based on the principle that CD33-positive AML-restricted apoptosis induction by scFvCD33:sTRAIL B ten Cate et al tumor cells are not only eliminated by scFvCD33:sTRAIL, but they are also exploited to crosslink agonistic TRAIL receptors on neighboring tumor cells lacking CD33 expression (Figure 3a) . Jurkat.CD33 and Jurkat cells mixed at a ratio of 1:1 were treated for 6 h with identical amounts of scFvCD33:sTRAIL (727 ng/ml) or scFvC54:sTRAIL (727 ng/ml). Differential analysis of apoptosis in the Jurkat.CD33 target cell population and the Jurkat bystander cell population showed that scFvCD33:sTRAIL, but not scFvC54:sTRAIL, potently induced apoptosis in both the target and bystander tumor cell populations. (Figures 3b and c) .
Together this shows that in the presence of CD33-positive tumor cells, scFvCD33:sTRAIL has a potent anti-tumor bystander activity towards CD33-negative tumor cells. Earlier, we showed this potent anti-tumor bystander activity for various analogous tumor-selective scFv:sTRAIL fusion proteins. [16] [17] [18] This antitumor activity may be important to eliminate cancer cells that would otherwise escape from GO-based therapy due to partial loss of target antigen expression. In contrast, no anti-leukemia bystander activity towards CD33-negative AML cells can be conveyed by GO, as its activity critically depends on consecutive steps of first internalization followed by intracellular processing and nuclear translocation of the calicheamicin toxin. Furthermore, separate evaluation of the activation of caspases 8 and 3/7 in Jurkat.CD33 target and Jurkat bystander cells indicated that in both cell populations caspase 8 and 3/7 are elevated after treatment with scFvCD33:sTRAIL (Figures 3d and e) . Currently, various new agents have been reported that have promising antileukemic activity, including type II topoisomerase inhibitor mitoxantrone, histone deacetylase inhibitor VPA, 28, 29 Hsp90 inhibitor 17-AAG 30, 31 and Bcr-Abl inhibitor Gleevec. 32 Combination treatment of scFvCD33:sTRAIL with mitoxantrone resulted in a synergistic apoptosis induction in MonoMac-6 and an additive apoptosis induction in U-937 tumor cells (CI ¼ 0.88 and 0.93, respectively, Figure 4a ). Treatment in which scFvCD33:sTRAIL is combined with either VPA or 17-AAG resulted in synergistic apoptosis induction in U-937 cells with cooperativity indexes of CI ¼ 0.52 and CI ¼ 0.77, respectively (Figure 4b ). Of note, similar synergistic induction of apoptosis was observed when scFvCD33:sTRAIL treatment was combined with cytarabine (data not shown). This indicates that various combinatorial treatment regimens with novel anti-cancer agents can rapidly be designed to result in enhanced or synergized anti-AML activity of scFvCD33:sTRAIL.
Subsequently, we assessed the anti-leukemia activity of scFvCD33:sTRAIL towards CD33-positive CML cells. About 95% of the CML cases are characterized by the Philadelphia translocation that is responsible for the production of Bcr-Abl, a constitutively active mutant tyrosine kinase that causes uncontrolled cellular proliferation. Bcr-Abl-selective kinase inhibitor Gleevec (imatinib mesylate) was approved by the FDA for the treatment of CML, and is currently used as first-line therapy. Unfortunately, gleevec-resistant relapses occur frequently after therapy interruption or cessation. Therefore, we evaluated the activity of scFvCD33:sTRAIL towards Bcr-Abl-positive/ CD33-positive CML cell lines K-562 and BV-173 and combined treatment with Gleevec. Both K-562 and BV-173 cells proved to be resistant to single-agent treatment with scFvCD33:sTRAIL. This is in line with a recent report that showed that the Bcr-Abl translocation contributes to TRAIL-resistance. 33 However, when scFvCD33:sTRAIL treatment was combined with Gleevec, synergistic apoptosis induction was observed in both K-562 and BV-173 cells (CI ¼ 0.36 and 0.54, respectively, Figure 4c ). This indicates that scFvCD33:sTRAIL may also be of therapeutic value for the treatment of CD33-positive CML when combined with Gleevec.
The activity of scFvCD33:sTRAIL towards AML tumor cell lines may not reliably reflect its activity towards primary patientderived AML tumor cells. Therefore, we evaluated the antileukemia activity of scFvCD33:sTRAIL towards primary AML samples that were freshly derived from three newly diagnosed AML patients. Single-agent treatment with scFvCD33:sTRAIL potently induced apoptosis in 3 out of 3 primary AML samples (Figures 5a-c) . Co-treatment with VPA enhanced apoptosis induction in 2 out of the 3 samples; in patient no. 1 apoptosis induction by scFvCD33:sTRAIL was synergistically enhanced (13.1-33.8% CI ¼ 0.46, Figure 5a ), whereas in patient no. 2 apoptosis was additively enhanced (55.4-73.2% CI ¼ 1.08, Figure 5b ). Unexpectedly, in patient no. 3 scFvCD33:sTRAIL co-treatment with VPA resulted in an antagonistic effect (24.2-10.4% CI ¼ 2.88). Usually, addition of VPA potentiates the antiproliferative effects of anti-leukemia agents and increases sensitivity of tumor cells to apoptosis induction. However, the precise mode of action of VPA and other histone deacetylase inhibitors is currently not fully understood. We found no obvious explanation for the observed antagonistic effect. Further study to explain this finding is warranted.
Unfortunately, due to clinical conditions, the availability of blood from patient no. 1 was limited. Therefore, only samples from patient no. 2 and 3 were subjected to treatment with scFvCD33:sTRAIL, which was combined with either mitoxantrone or 17-AAG. The results indicated that combination treatment with mitoxantrone synergistically enhanced scFvCD33:sTRAIL-induced apoptosis in patient no. 2 (55.4-81.5%; CI ¼ 0.78, Figure 5b ) and additively enhanced in patient no. 3 (24.2-54.0% CI ¼ 1.00, Figure 5c ). Hsp90 inhibitor 17-AAG synergistically enhanced the anti-leukemia activity of scFvCD33:sTRAIL towards AML cells from both patients no. Figures 5b and c) .
In conclusion, scFvCD33:sTRAIL is a novel potent antileukemia agent with CD33-restricted pro-apoptotic activity that shows no signs of toxicity towards normal monocytes. Moreover, scFvCD33:sTRAIL is superior to GO in terms of tumor selectivity, activity and stability. scFvCD33:sTRAIL showed a potent anti-AML bystander activity towards CD33-negative tumor cells, which may be important for the elimination of AML cells with lossed or heterogeneous CD33 expression. scFvCD33:sTRAIL showed promising anti-leukemic activity towards primary AML samples that were freshly derived from newly diagnosed AML patients. The activity of scFvCD33:sTRAIL could be enhanced by various novel anti-tumor agents. Therefore, we conclude that further development of scFvCD33:sTRAIL may expand treatment options of CD33-positive leukemias.
